INDEX 829
cytology, 43–48
acetate tape preparation, 47, 58
for deep mycoses, 524,533–534
direct impression smears, 46,53–55
for epitheliotropic lymphoma,55,368, 378
fine-needle aspiration, 46–47,56–57
for leishmaniasis, 462, 465
forMalasseziadermatitis, 46, 47,53–54,482, 492
for mast cell tumors, 496, 509
for mycobacterial infections, 514
for nocardiosis, 538
for otic disease, 45–46,53,547–548
skin scrapings, 43–44,48–49
squeeze tape impressions, 44–45
trichograms, 44,50–52
Cytomelseeliothyronine
Cytopointseelokivetmab
Cytoxanseecyclophosphamide
dacarbazine, 369
dachshund, 735–736
acanthosis nigricans, 433, 446
allergic contact dermatitis, 266
autoimmune blistering diseases, 189, 190
claw disorders, 589
color dilution alopecia, 434
ear margin dermatosis/vasculitis, 62,103,433,445,
699
hyperadrenocorticism, 395
hypothyroidism, 417
idiopathic nodular panniculitis, 65, 563
idiopathic sterile granuloma, 589, 598
Malasseziadermatitis, 481
mast cell tumors, 495
onychorrhexis, 66,135,589,595–596
primary seborrhea, 433
sebaceous gland adenoma/hyperplasia, 673
uveodermatologic syndrome, 692
dalmatian, 736
acral lick dermatitis, 228
actinic dermatoses, 575, 616
atopic disease, 175
cutaneous adverse drug reactions, 273
panniculitis, 563
pedal folliculitis and furunculosis, 214
squamous cell carcinoma, 673
vitamin A-responsive dermatosis, 62
danazol, 764
Dandie Dinmont terrier, 736
Danocrineseedanazol
Dantriumseedantrolene sodium
dantrolene sodium, 765
dapsone, 702, 765
Darier’s sign, 495,500–501
o,p’-DDDseemitotane
Decadronseedexamethasone
Decaject SPseedexamethasone
deerflies (Chrysopsspp.), 240
dell, 39
Delta-Cortefseeprednisolone
Deltasoneseeprednisone
d’embleeform of epitheliotropic lymphoma, 367
Demodex canis, 296, 300
skin scrapings, 44,49,299, 304
trichogram,50, 311
Demodex cati, 297
identification, 44, 298, 299, 306
Demodex cornei, 297
identification, 43, 299, 300, 305
Demodex felis, 297, 299, 306
Demodex gatoi, 297, 298
clinical features, 298, 299
identification, 43, 299, 300, 306
Demodex injai, 297
clinical features, 298, 310
identification, 44, 299, 305
demodicosis, 296–304
canine hyperadrenocorticism, 395, 407
clinical features, 64, 298–299,307–310
generalized alopecia, 60,81,298,307–308
localized alopecia, 59,69–70,298–299,307, 310
pododemodicosis,132,298,309, 599
course and prognosis, 303–304
diagnostics, 299–300
skin scrapings, 43–44,49,299, 304
squeeze tape impressions, 44–45
trichograms, 44,50,299, 311
differential diagnosis, 177, 299
juvenile-onset generalized (dog), 296, 297,307–308
signalment/history, 297–298
therapeutics, 300–303
dendritic cells (DC), 174
Depo-Estradiol Cypionateseeestradiol cypionate
Depo-Medrolseemethylprednisolone
Depo-Proveraseemedroxyprogesterone acetate
Depo-Testosteroneseetestosterone
L-deprenyl (selegiline), 402, 403, 809
deracoxib, 765
Deramaxxseederacoxib
Dermacenter andersoni, 243
Dermacenter occidentalis, 243
Dermacenter variabilis, 243
dermatofibrosis, nodularseenodular dermatofibrosis
dermatomyositis, canine familial, 312–316, 700
associated conditions, 316
clinical features, 313,317–319, 707–708
alopecia, 60, 78
claw disorders, 589, 595
depigmentation, 65, 319
nasal planum, 67
complications and prognosis, 315–316
pregnancy, 316
therapeutics, 314–315
dermatophytes, 28–30
culture and identification, 28, 29,33–34,322–323,
334–335